お知らせ • Jan 22

Valneva Announces U.S. FDA Approval of Its Chikungunya Vaccine, Ixchiq

Valneva SE reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to this age group in the U.S., Europe, and Canada. Data from this trial are also expected to support licensure of IXCHIQ® in Brazil, which would be the first potential approval for use in endemic populations. The one-year VLA1553-321 data showed that a single-dose vaccination induced a high, sustained immune response in an immunogenicity subset of participants who were CHIKV negative at baseline, with a seroresponse rate of 98.3% (232 out of 236 participants) one year after vaccination (Day 360) compared to 99.1% (232 out of 234 participants) after six month3 (Day 180) and 98.8% (248 out of 251 participants) 28 days after vaccination. The results complement the long-term persistence data previously reported for adults, confirming a strong and long-lasting antibody response to the vaccine. Geometric mean antibody titers (GMTs) consistently surpassed the seroresponse threshold defined with the U.S. Food and Drug Administration (FDA) as the surrogate of protection in baseline seronegative participants who received a single dose of the vaccine. Additionally, the one-year data confirmed that a single dose of the vaccine was generally well tolerated in adolescents. Throughout the trial, an Independent Data Safety Monitoring Board (IDSMB) consistently assessed safety data and found no safety issues. Conducted in collaboration with Instituto Butantan in Brazil and funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the European Union (EU)’s Horizon 2020 program, the VLA1553-321 trial represents the first clinical trial conducted in an endemic area and with individuals previously infected with CHIKV. This trial supported the submission of label extension applications to the U.S. Food and Drug Administration (FDA)8, the European Medicines Agency (EMA) and Health Canada to potentially extend the use of IXCHIQ® to adolescents aged 12 to 17 years. Data from this trial may support regulatory approval of the vaccine in Brazil and other countries in Latin America. Valneva expanded its partnership with CEPI, with support from the EU’s Horizon Europe programme, in the third quarter of 2024 through a $41.3 million grant to advance broader access to the vaccine in LMICs, including outbreak-affected countries, post-marketing studies and potential label extensions in children, adolescents and pregnant women. Within the framework of this agreement, Valneva recently announced the signing of an exclusive license agreement with the Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, enabling the supply of the vaccine in Asia, with a commitment to priority supply of the chikungunya vaccine at an affordable price to public health markets in LMICs. IXCHIQ® is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The vaccine is currently approved in the U.S., Europe, and Canada for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. In addition to Brazil, Valneva also expects to receive marketing approval in the United Kingdom in the first quarter of the year. VLA1553-321 is a prospective, double-blinded, multicenter, randomized, placebo-controlled pivotal Phase 3 trial conducted in 754 adolescents aged 12 to 17 years old in Brazil. The VLA1553-321 clinical trial was initiated in January 2022 and Valneva reported immunogenicity and safety data 28 days and six months after a single vaccination in 2023 and 2024 respectively. Valneva’s chikungunya vaccine or placebo was administered as a single intramuscular immunization to participants who were randomized into two study groups at a 2:1 ratio. The primary objective was to evaluate the immunogenicity and safety of the adult dose of the vaccine in adolescents 28 days following a single vaccination. Secondary objectives of the trial included assessment of safety and immunogenicity up to twelve months following a single vaccination with the vaccine. Additional information, including a detailed description of the study design, eligibility criteria and investigator sites, is available at ClinicalTrials.gov (Identifier: NCT04650399). Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years. In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.

Seeking Alpha • Aug 08

Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love

Valneva is a specialty vaccines company with an ongoing travelers vaccine business. Two major catalysts are around the corner: a BLA for chikungunya vaccine and a Phase 3 trial for the world’s only Lyme vaccine candidate. The company is trading near the low end of its 52-week range, with Pfizer having recently taken an 8.1% stake. Earnings, due August 11, 2022, may be interesting as they may reflect a Covid-unwinding world. The caveat is whether the market correctly appraised the future of its Covid vaccine. Thesis Valneva (VALN) is a French specialty vaccines company which has not been covered on Seeking Alpha after its Nasdaq IPO, even though it sports a market cap of $1.1 billion. It has operating sites all over the world, four of which in Europe and one in both Canada and the US, and has +750 employees worldwide. It has an ongoing travelers health business which I believe may report good results in the coming quarter, probably also with R&D expenses for the quarter reduced. VLA2001, Valneva’s inactivated Covid-vaccine which has strong efficacy across different variants, a good safety profile and booster potential, is currently suffering from an oversupply of Covid-vaccines, at least in the Western world. There may be an occasion here in the longer term, as a shift towards better vaccines than those currently used occurs. In the second half of 2022, Valneva will file for a biologics license application ((BLA)) for VLA1553, its Chikungunya vaccine candidate. This vaccine candidate has fast-track designation in the US, prime designation in the EU, and is eligible for a priority review voucher. VLA1553 has shown excellent safety and immunogenicity results and seems best placed to become the go-to vaccine for this disease. In the third quarter of 2022, Valneva will initiate a Phase 3 trial for VLA15, the world’s only Lyme vaccine candidate, which is again shown to be safe and efficacious. Pfizer (PFE) co-develops this vaccine, has provided serious funding, will pay more as milestones progress, and has just recently taken an 8.1% stake in Valneva. I see a buying opportunity here, with two important catalysts ahead, i.e. the BLA for the chikungunya vaccine and the Phase 3 trial initiation for the Lyme vaccine candidate. The fact that Pfizer saw the interest in the Lyme vaccine adds to my conviction. With about €300 million in the bank, I believe the market’s current valuation of Valneva is too low. I do see one caveat, and that would be that the market hasn’t fully discounted poor revenue coming from Valneva’s Covid vaccine. The current share price The company trades both on Euronext and on the Nasdaq, with much less liquidity on the latter. On Euronext, it trades under the ticker 'VLA', with a year-high of €29.7 and a year-low of €7.26. Its one-year chart is as follows. Trading on Euronext is more liquid. Valneva stock price chart Euronext (Google) On the Nasdaq, where the company trades under the ticker 'VALN', its yearly trading range is in between $67.84 and $13.71, with the company now trading around $20. Contrary to Euronext, there is little liquidity on the Nasdaq. There has been volatility in the stock price lately due to negative sentiment surrounding the commercial viability of the Covid vaccine program on the one hand, and positive sentiment relating to the recent €90.5 million stake of Pfizer in Valneva on the other. I will cover Valneva’s portfolio below as a function of each asset’s maturity in the business. I see most potential in both the chikungunya and Lyme disease candidates. Contrary to its Covid-vaccine, I believe those vaccines will not face serious competition, if any, once approved. Hence, I am looking at this company in part as a biotech company with a high-value late-stage pipeline, a fully operational manufacturing and commercial team, and a recovering ongoing business. Valneva’s ongoing business: traveler health portfolio and third-party distribution Valneva’s Traveler Health portfolio includes two vaccines, Ixiaro/Jespect and Dukoral, and encompasses vaccines for those traveling to other countries. Ixiaro, commercialized under the name Jespect, is a vaccine for Japanese encephalitis. Dukoral is a vaccine for the cholera and prevention of diarrhea resulting from an enterotoxigenic E. Coli bacteria. This business, covering approvals in most countries in the Western world, had been heavily impacted by travel restrictions and Covid-related lockdowns, mostly in 2020. Revenues declined from $130 million in 2019 to $66 million in 2020 and $63 million 2021, which still saw an impact from the pandemic. US soldiers travel too, and Valneva in fact derives quite some revenue from its long-standing relationship with the US government. The US military has an ongoing 3-year supply contract with Valneva for Ixiaro, and has been using that vaccine for more than 10 years already. The total minimum value of this contract is $118 million. I expect Valneva to report good numbers here for the second and third quarter of 2022. Valneva also commercializes third-party products such as Moskito Guard, Encepur, Flucelvax Tetra, Fluad, Kamrab and Rabipur, amounting to $15.4 million in 2021. It also has some minor other revenues. VLA2001, an inactivated COVID-19 vaccine VLA2001 is an inactivated virus vaccine which has shown robust efficacy and safety against different variants. It applies the same technology as Ixiaro’s, and consists of inactivated Covid-19 particles with preservation of the native structure of Covid-19’s spike-protein. It can be stored at cold chain temperatures (2-8° Celsius), can be used as primary vaccination or as a booster, and is suitable for routine immunization in the longer term. The Phase 3 trial results showed superiority in neutralizing antibody levels and a better safety profile compared to AZD1222, another EMA-approved vaccine. It has received standard marketing authorization in the EU, conditional marketing authorization in the UK, and emergency use authorization in Bahrain and the UAE. Q3 2022 should see Valneva readout its booster data, which I do not expect the market to react to. Here comes the catch though. Due to oversupply of vaccines in the Western world at this, this vaccine has yet to turn into a commercial success. The UK government had terminated its contract to order several million doses in 2021, which has led to a +$200 million settlement agreement in that year, which led the company to report total revenue of €348.1 for that year, compared to €110.3 million in 2021. I do add that 2020 and 2021 were weak years as the company’s travelers health portfolio revenue was seriously impacted by Covid. In 2019, revenue from the travelers health portfolio had been €129.5 million. The EU has recently expressed its wish to terminate its supply agreement with Valneva to supply up to 60 million doses over a period of two years, which led the stock to sell-off to its year-low in June 2022. The company is in talks with the EU about a remediation plan, as several EU countries have expressed their wish to receive the vaccine. I have seen an analyst write that Valneva may accept a ‘best-we-can-do’ offer to reduce stock inventories. Valneva has nonetheless clearly stated that, if volume indications would be too low, commercialization would not be sustainable. In that sense, I believe the company will have to revise its sales guidance expressed for 2022, but I believe the market has taken that into account. In the longer run, as the world may be ready for better and longer-lasting vaccines than the ones that are currently mainstream, this vaccine may attract business. VLA1553, the chikungunya vaccine candidate VLA1553 is one of three chikungunya vaccine candidates in development, probably best-in-class and furthest-progressed. Chikungunya is carried by mosquitoes in tropical and sub-tropical environments such as the Americas, India, and Thailand. It is prone to cause outbreaks among the population with a severe economic impact. Morbidity is low, but the inflammatory burden and persistent joint pain have a debilitating impact. VLA1553 overview slide (Valneva corporate presentation) The Phase 3 trial results showed outstanding immunogenicity and led to protective chikungunya neutralizing antibody titers in 98.5% of participants 28 days after single-dose administration. That 98.5% seroprotection rate exceeded the bar of 70% that had been agreed with the FDA. VLA1553 has basically been racking up regulator’s favoritism, with fast-track and prime designation respectively by the FDA and the EMA, and breakthrough therapy designation by the FDA in July 2021. Valneva is now likely to receive a priority review voucher, as sponsor of the first chikungunya vaccine to be approved in the US. Valneva would include VLA1553 in its travelers health portfolio with approval in the US and the EU underway. It has also entered into an agreement with the Brazilian ‘instituto butantan’ to commercialize this vaccine for less developed countries. Valneva is about to file for a BLA any time now, as it had been announced for mid-2022. I believe this could be a substantial catalyst for this drug candidate. Upon approval, launch can be expected soon after, with the plus here that Valneva has its commercial network set up already. In a global market which is to exceed $500 million by 2032, it can capture that market upon approval and establish its go-to position for years to come. I have read an analyst forecast risk-adjusted peak sales of €260 million by 2028. The above means that upon approval, this business has the potential of tripling the current sales revenue over time. VLA15, the Lyme disease vaccine candidate VLA15 is the biggest horse in the stable in my eyes, as the only Lyme vaccine candidate in the world, with outstanding Phase 2 data, which came in different sets of data over different studies, and huge Pfizer backing/involvement. Lyme disease is commonly known to most people. It is caused by the Borrelia burgdorferi bacteria, is transmitted by ticks and highly present in several regions of the Western world, where it expands more and more due to climate change. Lyme disease incidence slide (Valneva corporate presentation) Most patients recover, but 10-20% have persistent and sometimes disabling issues such as ongoing fatigue. There is currently no vaccine for Lyme disease available in the world, and although antibiotic treatments may provide relief, these generally come too late because detection of the disease is slow, and the therapeutic window passes. VLA15 has shown strong immune responses across 6 different serotypes. In April 2022, Valneva has reported results of its phase 2 pediatric study showing strong immunogenicity and an outstanding safety profile. These results build on earlier successful Phase 2 results, which is perhaps why the market has not given them much attention, if any. The upcoming catalyst here is the initiation of a phase 3 trial the second half of 2022, the results of which could be expected by year-end 2023. In the US and Europe combined, about 700,000 people each year are diagnosed with Lyme disease, with this number on the rise due to climate change. Pfizer and Valneva have a co-development and co-commercialization partnership here, with development-costs being split 60/40 for Pfizer and Valneva, respectively, and Valneva eligible for milestone payments. Of these milestone payment, $168 million are still to be paid. Initiation of the Phase 3 study, which is for any time now, will lead to a $25 million payment. The Pfizer involvement should ensure perfect marketing and commercialization potential. The most recent terms of the royalty agreement, as recently revised, are tiered royalties ranging from 14% to 22%. Add to that, Valneva is eligible for up to $100 million in milestone payment from Pfizer based on cumulative sales. I will also add to that, Pfizer is flush with cash and apparently on a buying spree. Latest rumors, as reiterated in this Seeking Alpha editor coverage on prognosis for the biotech sector in the current quarter, include rumors of Pfizer being in talks to buy Global Blood Therapeutics (GBT) in a $5 billion deal. In my earlier Cardiff Oncology (CRDF) coverage, I had recalled how earlier Pfizer equity investments led to buyouts. An 8.1% stake of Pfizer may bode well here, but I have difficulties to believe that would be a short-term scenario as parties have just revised their deal. I’ll add that Pfizer seems most interested in Valneva’s Lyme business, which I assume could not be included in Valneva’s travelers health portfolio. If one would assume a 400-million-person worldwide market with 3% penetration (i.e. 12 million), and pricing of $100 in the US and €50 in the EU which would be equally split between the two main markets, one arrives at sales numbers of $1.2 billion and €600 million, respectively. Assuming royalties to be around 18% (the middle of 14% and 22%), revenues would be $216 million for the US and €108 million for the EU. These are only vague estimates at this stage, as pricing is unknown and the concrete markets are unexplored, but they do give an idea of the value-driving potential here. Pfizer is seeing it, and again, there is no competition for this vaccine in the pipeline. First quarter 2022 results and second quarter expectations The results reported by Valneva for Q1 2022 were about the same as those reported for the year before. Total revenue was €21.8 million compared to €23.2 million in 2021, with product sales of €16.2 million compared to €16.1 million in 2021, and with first COVID-19 vaccine sales of €3.8 million. A total of €5.6 million were derived from other revenues, compared to €7.1 million in 2021. As Valneva’s business had been severely impacted by Covid-measures, I expect to see an uptick in business results for the coming quarter, as people are resuming travel again similar to pre-pandemic times to countries where the vaccines in the traveler’s health portfolio are of use. Valneva highlights in its corporate presentation that this business represented $130 million in 2019 when it was growing strongly (slide 18), and is a key asset for the future. Guidance in the Q1 results on May 5, 2022, was that Valneva expected its 2022 revenues to be within the range announced in February, namely €430 million to €590 million. I expect this guidance is no longer applicable in light of the recent termination or termination discussions with regards to the Covid vaccine, both in the UK and in the EU. I do believe the market has already discounted the future revision of that guidance, which one can see in the share price dip right after the Covid-update the company issued on June 10, 2022. Already for the first quarter of 2022, R&D costs were reduced to €20.7 million, where they were still €27.7 the year before. This was mainly attributable to ending of the Phase 3 trial for chikungunya and lower investments for the Covid-vaccine. I don’t expect to see any major R&D costs for the second quarter of 2022, as the Phase 2 trials for Lyme disease have now also ended. The reduction of R&D expenses for Q2 2022 that I expect may also have a considerable impact on operating and EBITDA loss compared to previous quarters. For Q1 2022, Valneva’s operating loss was €18.4 million versus €31.1 million in Q1 2021. Q1 2022 adjusted EBITDA loss was €12.7 million compared to €28.3 million in Q1 2021. Financials These were Valneva’s 2021 financial results as reported on March 24, 2022. Valneva 2021 financial results (Valneva Full Year 2021 reporting) Total revenues in 2021 were €348.1 million, compared to €110.3 million in 2020, but of that €348.1 million, €253.3 million was attributable to a settlement under the terminated UK agreement. Revenues from normal business, affected by Covid, were €94.8 million. As these were $130 million in 2019 and were apparently on the rise, I expect Valneva to do better here in Q2 2022 than compared to last quarter or last year’s second quarter. Valneva is flush with cash and will be so for the foreseeable future. Its cash position end of March 2022 €311.3 million. In April 2020, Valneva entering into an R&D agreement with Pfizer for the Lyme vaccine candidate, which led to an upfront payment of $130 million in June 2020. Pfizer is due to pay an additional $178 in development milestones, among which $25 million when the vaccine candidate enters Phase 3 trials. In May 2021, Valneva picked up $107.6 million as a result of a global Offering and Nasdaq listing, which was followed by an additional global offering worth $102 million. The collaboration agreement with Pfizer has been adapted in June 2022, with Pfizer taking an equity investment in Valneva of 8.4% for a total of $90.5 million, and with parties agreeing a slightly different royalty split. Finally, a financing arrangement with US healthcare funds Deerfield and Orbimed led to the availability of an additional $40 million in April 2022. A fair value for Valneva’s business potential As mentioned above, given its pipeline, I am looking at Valneva as an ongoing business with an even bigger pipeline.

Biotechs 収益成長	24.7%
収益成長率	20.4%
将来の株主資本利益率	18.70%
アナリストカバレッジ	Good
最終更新日	30 Apr 2026

日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	264	32	-4	86	6
12/31/2027	312	68	72	96	9
12/31/2026	165	-64	-57	-50	9
12/31/2025	175	-115	-57	-53	N/A
9/30/2025	180	-102	-19	-19	N/A
6/30/2025	196	-67	-27	-12	N/A
3/31/2025	186	-80	-60	-47	N/A
12/31/2024	170	-12	-84	-67	N/A
9/30/2024	159	-7	-169	-143	N/A
6/30/2024	156	-32	-215	-204	N/A
3/31/2024	153	-24	-222	-207	N/A
12/31/2023	154	-101	-217	-203	N/A
9/30/2023	223	-113	-208	-193	N/A
6/30/2023	426	-7	-231	-211	N/A
3/31/2023	373	-135	-267	-243	N/A
12/31/2022	361	-143	-275	-245	N/A
9/30/2022	439	73	-195	-149	N/A
6/30/2022	304	-159	-177	-108	N/A
3/31/2022	347	-72	-83	2	N/A
12/31/2021	348	-73	-16	77	N/A
9/30/2021	121	-248	15	97	N/A
6/30/2021	110	-125	51	109	N/A
3/31/2021	98	-91	147	182	N/A
12/31/2020	110	-64	118	138	N/A
9/30/2020	104	-62	67	78	N/A
6/30/2020	120	-25	97	105	N/A
3/31/2020	127	-8	-7	3	N/A
12/31/2019	126	-2	-5	6	N/A
9/30/2019	116	4	N/A	10	N/A
6/30/2019	109	1	N/A	16	N/A
3/31/2019	116	7	N/A	17	N/A
12/31/2018	113	3	N/A	16	N/A
9/30/2018	107	-7	N/A	6	N/A
6/30/2018	110	-7	N/A	10	N/A
3/31/2018	108	-8	N/A	5	N/A
12/31/2017	105	-11	N/A	13	N/A
9/30/2017	103	-11	N/A	17	N/A
6/30/2017	100	-14	N/A	19	N/A
3/31/2017	102	-46	N/A	25	N/A
12/31/2016	98	-49	N/A	7	N/A
9/30/2016	93	-63	N/A	4	N/A
6/30/2016	96	-61	N/A	-5	N/A
3/31/2016	89	-35	N/A	-17	N/A
12/31/2015	83	-21	N/A	-20	N/A
9/30/2015	74	-16	N/A	-24	N/A
6/30/2015	65	-13	N/A	-19	N/A

データ	最終更新日（UTC時間）
企業分析	2026/05/07 17:11
終値	2026/05/07 00:00
収益	2025/12/31
年間収益	2025/12/31

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

アナリスト	機関
Vladimira Urbankova	Erste Group Bank AG
Simon Scholes	First Berlin Equity Research GmbH
Rajan Sharma	Goldman Sachs

Valneva 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Valneva SE Reiterates Earnings Guidance for the Year 2026

Valneva SE Reiterates Earnings Guidance for the Year 2025

Valneva SE Revises Earnings Guidance for the Year 2025

Valneva SE Provides Earning Guidance for the Fiscal Year 2025

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva Se Announces Earnings Guidance for 2024

Recent updates

Valneva SE has filed a Follow-on Equity Offering in the amount of €37.032594 million.

Pfizer Inc. and Valneva SE Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor Trial

Valneva SE Reiterates Earnings Guidance for the Year 2026

Valneva SE Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom

Valneva SE to Report Q1, 2026 Results on May 07, 2026

Valneva Se and Instituto Butantan Announce Initiation of Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine Ixchiq

Valneva SE Provides Update on Chikungunya Vaccine IXCHIQ

Valneva SE to Report Fiscal Year 2025 Results on Mar 01, 2026

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Valneva SE Announces to Further Consolidate its Operations in France

Valneva SE Reiterates Earnings Guidance for the Year 2025

Valneva SE Revises Earnings Guidance for the Year 2025

Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns

Valneva SE Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ in the U.S

Valneva SE Announces Health Canada Grants Marketing Authorization for its Single-Dose Vaccine, IXCHIQ

Valneva SE Provides Earning Guidance for the Fiscal Year 2025

Valneva SE Chikungunya Vaccine IXCHIQ Restriction Lifted for Elderly

Valneva SE Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ®? in Elderly

Valneva SE Appoints Gerd Zettlmeissl to the Board

Valneva SE Announces Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for Its Single-Shot Chikungunya Vaccine Ixchiq

Valneva SE, Annual General Meeting, Jun 25, 2025

Valneva SE Provides Update on Recommended Use of IXCHIQ®? by Elderly Individuals in the United States

Valneva SE Provides Update Following European Medicines Agency Announcement on Use of Ixchiq®? in Elderly

Valneva SE Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva SE: Initiating Hold Rating Based On Potentially Limited Upside

Valneva SE Receives First Marketing Authorization for Single-Dose Vaccine IXCHIQ in A Chikungunya Endemic Country

Valneva SE and LimmaTech Biologics AG Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE's Chikungunya Vaccine IXCHIQ®? Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ, to UK MHRA

Valneva SE has filed a Follow-on Equity Offering in the amount of $75 million.

Valneva SE Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine Ixchiq

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ

Valneva SE Reports Positive Phase 2 Results in Children for Its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Valneva Is A 'Buy' As A First-Mover In Chikungunya

Valneva Announces U.S. FDA Approval of Its Chikungunya Vaccine, Ixchiq

Valneva SE Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva seeking a partnership for next-gen COVID-19 vaccine